Hepsera Related Published Studies
Well-designed clinical trials related to Hepsera (Adefovir Dipivoxil)
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2008.09]
The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. [2008.04]
Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. [2008]
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. [2007.12.04]
Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. [2007.12]
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. [2007.11.15]
Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. [2007.10.01]
[Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: A randomized, double-blind, multicenter clinical study.] [2007.09]
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. [2007.02]
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. [2006.12]
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. [2006.11]
[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B] [2006.11]
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. [2006.07]
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. [2005.06.30]
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. [2004.09]
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. [2004.01]
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. [2004.01]
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. [2004.01]
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. [2003.07]
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. [2003.07]
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. [2003.02.27]
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. [2003.02.27]
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. [2001.09.07]
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. [2001.08.15]
Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. [1999.12.22]
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. [1999.09]
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. [1998.07]
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. [1997.12]
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. [1997.08]
Well-designed clinical trials possibly related to Hepsera (Adefovir Dipivoxil)
Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. [2005.10.07]
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. [2003.01]
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. [2002.07.10]
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. [2000.11.10]
Other research related to Hepsera (Adefovir Dipivoxil)
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. [2008.07.21]
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. [2008.07]
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. [2008.06]
Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. [2008.06]
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. [2008.05]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2008.05]
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. [2008.04]
Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. [2008.03.21]
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. [2008.02.29]
Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. [2008.02.14]
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. [2008.02.01]
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. [2008.02]
Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. [2008.01]
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. [2007.12.31]
Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. [2007.12]
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. [2007.11.15]
[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period.] [2007.11]
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis] [2007.10.27]
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. [2007.10]
Effects of adefovir dipivoxil therapy in asian and caucasian patients with chronic hepatitis B. [2007.09.14]
[Diammonium glycyrrhizinate does not affect efficacy of adefovir dipivoxil therapy in patients with HBeAg-positive chronic hepatitis B.] [2007.09]
Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. [2007.09]
Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. [2007.08.14]
Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. [2007.08]
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. [2007.07]
[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients.] [2007.05]
Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. [2007.05]
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. [2007.05]
Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. [2007.05]
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. [2007.04.15]
[A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B] [2007.04]
[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil] [2007.04]
[A case of chronic hepatitis B with primary adefovir resistance] [2007.04]
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. [2007.03]
A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. [2007.02]
Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. [2007.02]
Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. [2007.01]
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma. [2007]
Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. [2007]
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. [2007]
A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. [2007]
[A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B.] [2006.12]
Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. [2006.12]
Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. [2006.11]
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. [2006.10]
Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis. [2006.09]
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. [2006.09]
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. [2006.08]
Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. [2006.08]
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. [2006.08]
Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. [2006.07.21]
Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. [2006.07]
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). [2006.06]
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. [2006.06]
Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. [2006.06]
[The change of HBV nucleotide sequence during Adefovir dipivoxil treatment] [2006.05]
Variant of hepatitis B virus with primary resistance to adefovir. [2006.04.27]
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. [2006.04]
Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. [2006.03]
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. [2006.02.01]
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. [2006.02]
[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B] [2006.02]
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. [2006.01]
Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. [2006]
Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. [2006]
[Safety and tolerance study of single oral dose of adefovir dipivoxil tablets in healthy volunteers] [2005.12]
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. [2005.12]
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. [2005.11]
|
